Approval

EU adds axial spondyloarthritis to Alfasigma's Jyseleca label

The European Commission cleared filgotinib for adults with axial spondyloarthritis, in either its radiographic or non-radiographic form, after inadequate response to conventional care. Across the OLINGUITO phase 3 program, more patients reached ASAS40 at week 16 on the JAK1-preferring drug than on placebo, with gains holding to week 52. A UK filing is pending.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Schematic animation of a cytokine binding its receptor on an immune cell, JAK enzymes on the inner side of the membrane tagging STAT proteins, and the small molecule filgotinib sitting on JAK1 so that fewer STAT proteins are tagged.
Filgotinib: preferential JAK1 blocking inside immune cells. Watch the mechanism animation on the filgotinib page.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call